Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336360 · ClinicalTrials.gov registry record · Phase 1
Augmenting Flortaucipir Dosimetry Estimates
A Phase 1 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02336360: Completed Phase 1 study, sponsored by Avid Radiopharmaceuticals.
NCT02336360 is a Phase 1 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02336360, a Phase 1 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.
Primary Outcome
Total integrated radioactivity excreted in urine over time will be determined to augment previous radiation dosimetry calculations.
Interventions
- DRUG Flortaucipir F18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
What the finished NCT02336360 record still lists
NCT02336360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Flortaucipir F18 is the first listed.
NCT02336360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02336360 about?
NCT02336360 is a clinical study titled "Augmenting Flortaucipir Dosimetry Estimates". This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.
What is the current status of trial NCT02336360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02336360?
The interventions under investigation include: Flortaucipir F18 (DRUG).
Who is sponsoring clinical trial NCT02336360?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02336360's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia